1. Additional file 1 of Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia
- Author
-
Tan, Yue, Shan, Lingling, Zhao, Liping, Deng, Biping, Ling, Zhuojun, Zhang, Yanlei, Peng, Shuixiu, Xu, Jinlong, Duan, Jiajia, Wang, Zelin, Yu, Xinjian, Zheng, Qinlong, Xu, Xiuwen, Tian, Zhenglong, Zhang, Yibing, Zhang, Jiecheng, Chang, Alex H., Feng, Xiaoming, and Pan, Jing
- Abstract
Additional file 1. Materials and Methods. Fig. S1. Severe GVHD associated with higher LDH and ferritin in blood. Fig. S2. The incidence and persistance of GVHD according to the degree of HLA matching. A Early GVHD in patients receiving haploidentical donor cells and matched unrelated donor or matched sibling donor cells (MUD/MSD). B Late-onset GVHD in patients receiving haploidentical donor cells and matched unrelated donor or matched sibling donor cells (MUD/MSD). C Persistence of early GVHD between patients receiving haploidentical donor cells and MUD/MSD cells. D Persistence of late-onset GVHD between patients receiving haploidentical donor cells and MUD/MSD cells. Fig. S3. EBV and CMV viral load in the plasma. A Copy numbers of CMV DNA in plasma of individual patients. B Copy numbers of EBV DNA in plasma of individual patients. Fig. S4. Kaplan-Meier curves of duration of response after CD7 CAR T-cell therapy. A Kaplan-Meier curves of duration of response in all responded patients after CD7 CAR T-cell therapy. B Kaplan-Meier curves of duration of response in subgroups according to SCT after CD7 CAR T-cell therapy. Fig. S5. Representative staining of T, NK and NKT cells in the peripheral blood of a patient. Fig. S6. CD4+ and CD8+ T cell ratio in the peripheral blood of all patients. Fig. S7. Characterization of CD7- T cells from patients post CD7 CAR T-cell therapy. A CD45RA, CD62L and CD95 expression on CD4+ and CD8+ T cells from E018 at month 20 post CD7 CAR T-cell therapy and a healthy donor, as determined by flow cytometry. B T cell receptor (TCR) sequencing data, including the sum of the sequencing reads, TCR clones reconstructing from the sequencing reads and shannon entropy as an index of TCR Vβ usage diversity from indicated patients and healthy donors. C The number of T cells secreting IFN-γ in PBMCs from indicated patients, and healthy donors, after stimulation with phytohemagglutinin (PHA, as positive control), cytomegalovirus (CMV) or Epstein-Barr virus (EBV) peptide, as determined by IFN-γ ELISPOT assay. Table S1. Adverse events of special interest in all 20 treated patients and by subgroups. Table S2. The degree of HLA matching and GVHD. Table S3. Chimerism status after CAR T-cell infusion in all 20 treated patients.
- Published
- 2023
- Full Text
- View/download PDF